Roxee Medication Guide

Firocoxib

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Chewable Tablets Multiple FDA sponsors Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts

Reference refreshed

Jun 22, 2026, 10:40 a.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

Jun 22, 2026, 10:40 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

Jun 13, 2026, 11:29 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:40 AM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Mar 3, 2026, 11:00 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC

Image coming soon

Firocoxib

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Chewable Tablets Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA sponsors

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Firocoxib

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs. For the control of pain and inflammation associated with osteoarthritis. For the control of pain and inflammation associated with osteoarthritis in horses. Species commonly shown: Both, Dog, Horse, Not For Meat Production.

Generic name

Firocoxib

Brand names

Previcox®, Equioxx® Oral Paste, Equioxx® Injection, Equioxx®

Manufacturer

Multiple FDA sponsors

Species

Both, Dog, Horse

Dosage forms

Chewable Tablets, Paste, Non-Aqueous Injectable Solution, Tablet

Prescription

Prescription required

Completeness

100%

Validation

Complete

Brand names

Previcox® Equioxx® Oral Paste Equioxx® Injection Equioxx® Firox™ Firocoxib Tablets for Horses Firocoxib Chewable Tablets for Dogs Firocoxib Firodyl™ EquiCoxib™

Dosage forms

Chewable Tablets Paste Non-Aqueous Injectable Solution Tablet Oral Solution

Indications / Uses

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.

Side Effects

Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Elevated blood urea nitrogen (BUN), Other abnormal test result NOS, Elevated creatinine.

FAQ

Both, Dog, Horse, Not For Meat Production

Yes. Roxee shows this as prescription-only.

Chewable Tablets, Paste, Non-Aqueous Injectable Solution, Tablet

Related Conditions

Osteoarthritis (Degenerative Joint Disease) Osteoarthritis (Degenerative Joint Disease) Pain (acute, chronic)

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/1281
Verified source: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/12710
Last refreshed: Jun 22, 2026, 10:40 a.m.
Last verified: Feb 12, 2026, 10:44 p.m.
Validation status: Complete

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the control of pain and inflammation associated with osteoarthritis.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

Do not use in horses intended for human consumption
For intravenous use in horses only
Vomiting (1 reports)
wobbly/unsteady walking (1 reports)
very low energy (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Firocoxib; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case DEU-USFDACVM-2025-DE-000039

Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 28 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case DEU-USFDACVM-2025-DE-000039

Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case DEU-USFDACVM-2025-DE-000039

Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Vomiting (1 reports), Unsteady walking (ataxia) (1 reports), Tiredness (lethargy) (1 reports), Loss of appetite (1 reports), Limb non-weight bearing (1 reports)

Body systems represented Signal grouping

Digestive (2), Skin & allergy (1), Neurologic (2), Effectiveness (1)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (27 reports), Cat (5 reports)

Breed metadata in reports Metadata only

Retriever - Labrador (2), Saint Bernard Dog (1), ['Pit Bull', 'Dog (unknown)'] (1), ['Boxer (German Boxer)', 'Dog (other)'] (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Firocoxib fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Do not use in horses intended for human consumption, For intravenous use in horses only, Vomiting, wobbly/unsteady walking, very low energy

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Firocoxib brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.

Vet source depth

openFDA case DEU-USFDACVM-2025-DE-000039 · adverse_reaction · adverse reactions
Contraindication source · fda_animal_drugs · warnings contraindications
FDA application profile · official_label · quick facts
FDA application profile · official_label · quick facts
Medication usage source · fda_animal_drugs · quick facts
FOI · document · documents
SPL · document · documents
FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
Previcox® · official_label
openFDA case DEU-USFDACVM-2025-DE-000039 · adverse_reaction

Safety & side effects

Side effects to monitor:

Do not use in horses intended for human consumption
For intravenous use in horses only
Vomiting
wobbly/unsteady walking
very low energy

Most reported reactions:

Vomiting (1 reports)
Unsteady walking (ataxia) (1 reports)
Tiredness (lethargy) (1 reports)

Explore reported case details

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species

Dog, Horse

Indication / use

For the control of pain and inflammation associated with osteoarthritis.

Form / route / dose

Form: Chewable Tablets, Non-Aqueous Injectable Solution, Oral Solution, Paste, Tablet
Route: Intravenous, Oral
Confirm product label and patient-specific plan.

Warnings

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for…

Adverse-event caveat

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Source docs

A-200755-G-0020-FL-AA_CIS.pdf Official label / PI
A-200755-G-0020-FL-AA_PI.pdf Official label / PI
N-141230-C-0093-NL-AA_CIS.pdf Official label / PI

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Multiple FDA sponsors

Form: Chewable Tablets, Non-Aqueous Injectable Solution, Oral Solution, Paste, Tablet

Identifiers:

ANADA: 200722 ANADA: 200726 ANADA: 200751 ANADA: 200755 ANADA: 200756 ANADA: 200766 ANADA: 200841 NADA: 141230 NADA: 141253 NADA: 141313 NADA: 141458 NDC Package: 0010-3309-01 NDC Package: 0010-3309-02 NDC Package: 0010-9140-02 NDC Package: 0010-9140-03 NDC Package: 0010-9140-06 NDC Package: 0010-9150-02 NDC Package: 0010-9150-03 NDC Package: 0010-9150-05 NDC Package: 11695-7018-1

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200841 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200755 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Stored reports

Matching reports

Active filters

Selected filters

Body system: Other Clear

Species

Breed

Size / weight

Age

Sex

Seriousness

Outcome

Reaction

Body system

Region

Received after

Received before

Reset

Drill into common report signals

Agitation (2) Ataxia (2) Death by euthanasia (2) Musculoskeletal disorder NOS (2) Other (6) Neurologic (2) Digestive (1) Skin & allergy (1)

Showing up to 50 matching reports.

USA-USFDACVM-2025-US-075505

Received 2025-12-18 · MSK · MSK

Non-serious

Species: Dog
Breed: Saint Bernard Dog
Size / weight: 100+ lb (58.06 Kilogram)
Age: 8+ years (1 Year)
Sex: Male Neutered
Region: USA
Reactions: Elevated blood urea nitrogen (BUN)Elevated creatinine
Body systems: Other
Outcomes: Outcome Unknown

USA-USFDACVM-2025-US-074653

Received 2025-12-09 · MSK · MSK

Serious

Species: Dog
Breed: ['Pit Bull', 'Dog (unknown)']
Size / weight: 50-99 lb (37.376 Kilogram)
Age: 8+ years (11.5 Year)
Sex: Female Neutered
Region: USA
Reactions: Joint swellingBone and joint disorder NOSSarcoma NOS
Body systems: Skin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2025-US-071673

Received 2025-12-02 · MSK · MSK

Serious

Species: Dog
Breed: Retriever - Labrador
Size / weight: 50-99 lb (24.494 Kilogram)
Age: 8+ years (13 Year)
Sex: Male Intact
Region: USA
Reactions: BloatedStaggeringDeathDry heavingDistension of abdomen
Body systems: Other
Outcomes: Died

USA-USFDACVM-2025-US-074731

Received 2025-11-25 · MSK · MSK

Non-serious

Species: Dog
Breed: Retriever - Labrador
Size / weight: 50-99 lb (44.452 Kilogram)
Age: 8+ years (9 Year)
Sex: Female Neutered
Region: USA
Reactions: VomitingNot eatingLow platelet count
Body systems: DigestiveOther
Outcomes: Outcome Unknown

USA-USFDACVM-2025-US-073418

Received 2025-11-24 · MSK · MSK

Serious

Species: Dog
Breed: ['Boxer (German Boxer)', 'Dog (other)']
Size / weight: 25-49 lb (21.047 Kilogram)
Age: 8+ years (1 Year)
Sex: Male Neutered
Region: USA
Reactions: Musculoskeletal disorder NOSAtaxiaWeaknessAgitationPantingDeath by euthanasia
Body systems: OtherNeurologic
Outcomes: Euthanized

USA-USFDACVM-2025-US-065912

Received 2025-10-31 · MSK · MSK

Serious

Species: Dog
Breed: ['Boxer (German Boxer)', 'Retriever (unspecified)', 'Bulldog - English']
Size / weight: 25-49 lb (21.047 Kilogram)
Age: 8+ years (1 Year)
Sex: Male Neutered
Region: USA
Reactions: Musculoskeletal disorder NOSAtaxiaWeaknessAgitationPantingDeath by euthanasia
Body systems: OtherNeurologic
Outcomes: Euthanized

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (2) · Vomiting, Loss of appetite Skin & allergy (1) · Joint swelling Neurologic (2) · Unsteady walking (ataxia), Tiredness (lethargy) Effectiveness (1) · Lack of efficacy - NOS Other (26) · Limb non-weight bearing, Leucopenia NOS, Leucocytosis NOS

Most Reported Reactions

Body system	Cases	Species	Serious cases
Digestive	1	Dog	1
Neurologic	1	Dog	1
Neurologic	1	Dog	1
Digestive	1	Dog	1
Other	1	Cat	1
Other	1	Dog	1
Other	1	Dog	1
Effectiveness	1	Dog	1

Species coverage: Dog (27) Cat (5)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Digestive	Dog	Serious	-	1
Neurologic	Dog	Serious	-	1
Neurologic	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Effectiveness	Dog	Serious	-	1
Skin & allergy	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case DEU-USFDACVM-2025-DE-000039

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

A-200755-G-0020-FL-AA_CIS.pdf Official label / PI · Labeling A-200755-G-0020-FL-AA_PI.pdf Official label / PI · Labeling N-141230-C-0093-NL-AA_CIS.pdf Official label / PI · Labeling

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

No owner handouts linked yet.

Official label / PI

SPL

Open original

FDA Structured Product Label

Firocoxib Tablets for Horses

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Felix Pharmaceuticals Pvt. Ltd.
ANADA: 200-841
Status: RX
Form: Tablet
Route: Oral

Composition / specifications

57 mg firocoxib per tablet

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis.

Dosage

Administer one 57-mg tablet to horses weighing 800 to 1,300 lb once daily for up to 14 days.

Firocoxib

SPL · SPL

Open original

FDA Structured Product Label

Firocoxib

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Felix Pharmaceuticals Pvt. Ltd.
ANADA: 200-755
Status: RX
Form: Chewable Tablets
Route: Oral
Species: Dog

Composition / specifications

57 mg or 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis; and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery.

Dosage

5 mg/kg (2.27 mg/lb) body weight. Administer once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours before soft-tissue or orthopedic surgery.

Previcox®

SPL · SPL

Open original

FDA Structured Product Label

Previcox®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Boehringer Ingelheim Animal Health USA, Inc.
NADA: 141-230
Status: RX
Form: Chewable Tablets
Route: Oral
Species: Dog

Composition / specifications

Each chewable tablet contains 57 or 227 mg firocoxib.

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Dosage

5 mg/kg (2.27 mg/lb) body weight once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours prior to surgery.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

EquiCoxib™

SPL · SPL

Open original

FDA Structured Product Label

EquiCoxib™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Aurora Pharmaceutical, Inc.
ANADA: 200-766
Status: RX
Form: Oral Solution
Route: Oral

Composition / specifications

9.0 mg/mL

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

0.045 mg/lb (0.1 mg/kg) of body weight once daily for up to 14 days

Firocoxib Chewable Tablets for Dogs

SPL · SPL

Open original

FDA Structured Product Label

Firocoxib Chewable Tablets for Dogs

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Pegasus Laboratories, Inc.
ANADA: 200-751
Status: RX
Form: Chewable Tablets
Route: Oral
Species: Dog

Composition / specifications

57 mg or 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Dosage

Firodyl™

SPL · SPL

Open original

FDA Structured Product Label

Firodyl™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Ceva Sante Animale
ANADA: 200-756
Status: RX
Form: Chewable Tablets
Route: Oral
Species: Dog

Composition / specifications

57 mg and 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery.

Dosage

Firox™

SPL · SPL

Open original

FDA Structured Product Label

Firox™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Norbrook Laboratories, Ltd.
ANADA: 200-722
Status: RX
Form: Chewable Tablets
Route: Oral
Species: Dog

Composition / specifications

57 mg and 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Dosage

2.27 mg/lb (5.0 mg/kg) body weight once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours prior to surgery.

Firocoxib Tablets for Horses

SPL · SPL

Open original

FDA Structured Product Label

Firocoxib Tablets for Horses

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Pegasus Laboratories, Inc.
ANADA: 200-726
Status: RX
Form: Tablet
Route: Oral

Composition / specifications

57 mg firocoxib per tablet

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

One 57 mg tablet administered orally to horses weighing 800 – 1300 lbs, once daily for up to 14 days.

Equioxx® Oral Paste

SPL · SPL

Open original

FDA Structured Product Label

Equioxx® Oral Paste

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Boehringer Ingelheim Animal Health USA, Inc.
NADA: 141-253
Status: RX
Form: Paste
Route: Oral
Species: Horse

Composition / specifications

Each milligram (mg) of paste contains 0.82 mg firocoxib.

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis.

Dosage

0.1 mg per kilogram (0.045 mg per pound) body weight daily for up to 14 days.

Limitations

Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Equioxx®

SPL · SPL

Open original

FDA Structured Product Label

Equioxx®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Boehringer Ingelheim Animal Health USA, Inc.
NADA: 141-458
Status: RX
Form: Tablet
Route: Oral

Composition / specifications

57 mg firocoxib

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

Administer one 57 mg tablet daily for horses weighing 800-1300 lbs for up to 14 days duration.

Limitations

For use in horses only. Do not use in horses intended for human consumption.

Equioxx® Injection

SPL · SPL

Open original

FDA Structured Product Label

Equioxx® Injection

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Boehringer Ingelheim Animal Health USA, Inc.
NADA: 141-313
Status: RX
Form: Non-Aqueous Injectable Solution
Route: Intravenous

Composition / specifications

20 mg firocoxib per mL

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

One intravenous injection once daily for up to 5 days, at a dose of 0.04 mg/lb (0.09 mg/kg) body weight (BW). If further treatment is needed EQUIOXX (firocoxib) Oral Paste for horses can be used at a dosage of 0.045 mg/lb (0.1 mg/kg) body weight for up to an additional 9 days of treatment. The overall duration of treatment EQUIOXX Injection and EQUIOXX Oral Paste will be dependent on the response observed, but should not exceed 14 days.

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/18152 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18470/Firocoxib%20Tablets%20for%20Horses · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/14442 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/2118 · document · Labeling
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/2119 · document · Labeling
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/14554/Firocoxib · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/770 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/769 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/768 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/405 · document · Labeling

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:40 AM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Mar 3, 2026, 11:00 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC

Official (FDA)

Identity: Generic ingredient • No FDA branded products linked

No official FDA brand rows linked yet for this ingredient.

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Dog, Horse

Rx/OTC: RX

Form/route: Chewable Tablets, Non-Aqueous Injectable Solution, Oral Solution, Paste, Tablet • Intravenous, Oral

Applications: ANADA 200-841 • ANADA 200-755 • NADA 141-230 • ANADA 200-766 • ANADA 200-751 • ANADA 200-756 • ANADA 200-722 • ANADA 200-726 • NADA 141-253 • NADA 141-458 • NADA 141-313

Documents: 28 (FOI: 13) • SPL: 11 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 19 • Cat 0 • View

Case summaries: 6 (showing 6) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Osteoarthritis (Degenerative Joint Disease) Osteoarthritis (Degenerative Joint Disease) Pain (acute, chronic)

Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

ICD10_CM: M19.90

Unspecified osteoarthritis, unspecified site

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only. (Contraindication, High)

Top reaction signals

Vomiting (1) Unsteady walking (ataxia) (1) Tiredness (lethargy) (1) Loss of appetite (1) Limb non-weight bearing (1) Leucopenia NOS (1) Leucocytosis NOS (1) Lack of efficacy - NOS (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
0010-3309-01	0010	-
0010-3309-02	0010	-
0010-9140-02	0010	-
0010-9140-03	0010	-
0010-9140-06	0010	-
0010-9150-02	0010	-
0010-9150-03	0010	-
0010-9150-05	0010	-
11695-7018-1	11695	-
11695-7018-2	11695	-
11695-7019-1	11695	-
11695-7019-2	11695	-
11695-7064-1	11695	-
11695-7064-2	11695	-
11695-7065-1	11695	-
11695-7065-2	11695	-
11695-7066-1	11695	-
11695-7066-2	11695	-
17033-720-18	17033	-
17033-720-60	17033	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

FOI Summary oA 200-841 Approved February 23, 2026.pdf • FOI summary • Official • March 2, 2026
FDA FOI summary for application 200841
A-200755-G-0020-FL-AA_PI.pdf • Official label • Official • April 24, 2025
FDA official labeling for application 200755
A-200755-G-0020-FL-AA_CIS.pdf • Official label • Official • April 24, 2025
FDA official labeling for application 200755
FOI Summary oA 200-755 Approved August 3, 2023.pdf • FOI summary • Official • April 24, 2025
FDA FOI summary for application 200755
N-141230-C-0093-NL-AA_PI.pdf • Official label • Official • April 24, 2025
FDA official labeling for application 141230
N-141230-C-0093-NL-AA_CIS.pdf • Official label • Official • April 24, 2025
FDA official labeling for application 141230
ucm118041.pdf • FOI summary • Official • April 24, 2025
FDA FOI summary for application 141230
ucm118042.pdf • FOI summary • Official • April 24, 2025
FDA FOI summary for application 141230
UCM218719.pdf • FOI summary • Official • April 24, 2025
FDA FOI summary for application 141230
A-200766-C-0002-CP-AA_CIS.pdf • Official label • Official • Oct. 3, 2024
FDA official labeling for application 200766
A-200766-C-0004-NL-AA_PI.pdf • Official label • Official • Oct. 3, 2024
FDA official labeling for application 200766
FOI Summary oA 200-766 Approved January 11, 2024.pdf • FOI summary • Official • Oct. 3, 2024
FDA FOI summary for application 200766
A-200751-G-0002-FL-AA_PI.pdf • Official label • Official • March 4, 2024
FDA official labeling for application 200751
FOI Summary oA 200-751 Approved June 22, 2023.pdf • FOI summary • Official • March 4, 2024
FDA FOI summary for application 200751
FOI Summary oA 200-756 Approved August 3, 2023.pdf • FOI summary • Official • Sept. 1, 2023
FDA FOI summary for application 200756
FIROX TABLETS 227mg 180x LBL.pdf • Official label • Official • Nov. 2, 2022
FDA official labeling for application 200722
A-200722-G-0004-FL-AA_CIS.pdf • Official label • Official • Nov. 2, 2022
FDA official labeling for application 200722
FOI Summary oA 200-722 Approved March 28, 2022.pdf • FOI summary • Official • Nov. 2, 2022
FDA FOI summary for application 200722
FOI Summary oA 200-726 Approved July 29, 2022.pdf • FOI summary • Official • Aug. 1, 2022
FDA FOI summary for application 200726
N-141253-C-0057-NL-AA_PI.pdf • Official label • Official • April 8, 2020
FDA official labeling for application 141253
N-141253-C-0057-NL-AA_CIS.pdf • Official label • Official • April 8, 2020
FDA official labeling for application 141253
UCM051453.pdf • FOI summary • Official • April 8, 2020
FDA FOI summary for application 141253
N-141458-C-0015-NL-AA_PI.pdf • Official label • Official • Dec. 17, 2019
FDA official labeling for application 141458
N-141458-C-0015-NL-AA_CIS.pdf • Official label • Official • Dec. 17, 2019
FDA official labeling for application 141458
UCM514663.pdf • FOI summary • Official • Dec. 17, 2019
FDA FOI summary for application 141458
UCM422171.pdf • Official label • Official • Nov. 13, 2017
FDA official labeling for application 141313
UCM422151.pdf • Official label • Official • Nov. 13, 2017
FDA official labeling for application 141313
UCM308268.pdf • FOI summary • Official • Nov. 13, 2017
FDA FOI summary for application 141313

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 97 Clinical 1 Manufacturer 0 Marketing 0

Current Field Facts

side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Elevated blood urea nitrogen (B… (Clinical, 2026-04-11)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restrict… (Official, 2026-04-12)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restrict… (Official, 2026-04-11)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restrict… (Official, 2026-02-12)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-22)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-22)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-21)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-20)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-13)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-12)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-12)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-11)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-11)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-10)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-09)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-08)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-07)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-06)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-05)
indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-06-04)

Recent Revisions

side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Firocoxib Tablets for Horses RX Firocoxib Tablet • Oral Label highlights Official documents	Felix Pharmaceuticals Pvt. Ltd.	ANADA 200-841	Approved	Mar 2, 2026
Firocoxib RX Firocoxib Chewable Tablets • Oral Label highlights Official documents	Felix Pharmaceuticals Pvt. Ltd.	ANADA 200-755	Approved	Apr 24, 2025
Previcox® RX Firocoxib Chewable Tablets • Oral Label highlights Official documents	Boehringer Ingelheim Animal Health USA, Inc.	NADA 141-230	Approved	Apr 24, 2025
EquiCoxib™ RX Firocoxib Oral Solution • Oral Label highlights Official documents	Aurora Pharmaceutical, Inc.	ANADA 200-766	Approved	Oct 3, 2024
Firocoxib Chewable Tablets for Dogs RX Firocoxib Chewable Tablets • Oral Label highlights Official documents	Pegasus Laboratories, Inc.	ANADA 200-751	Approved	Mar 4, 2024
Firodyl™ RX Firocoxib Chewable Tablets • Oral Label highlights Official documents	Ceva Sante Animale	ANADA 200-756	Approved	Sep 1, 2023
Firox™ RX Firocoxib Chewable Tablets • Oral Label highlights Official documents	Norbrook Laboratories, Ltd.	ANADA 200-722	Approved	Nov 2, 2022
Firocoxib Tablets for Horses RX Firocoxib Tablet • Oral Label highlights Official documents	Pegasus Laboratories, Inc.	ANADA 200-726	Approved	Aug 1, 2022
Equioxx® Oral Paste RX Firocoxib Paste • Oral Label highlights Official documents	Boehringer Ingelheim Animal Health USA, Inc.	NADA 141-253	Approved	Apr 8, 2020
Equioxx® RX Firocoxib Tablet • Oral Label highlights Official documents	Boehringer Ingelheim Animal Health USA, Inc.	NADA 141-458	Approved	Dec 17, 2019
Equioxx® Injection RX Firocoxib Non-Aqueous Injectable Solution • Intravenous Label highlights Official documents	Boehringer Ingelheim Animal Health USA, Inc.	NADA 141-313	Approved	Nov 13, 2017

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications

57 mg firocoxib per tablet

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis.

Dosage

Administer one 57-mg tablet to horses weighing 800 to 1,300 lb once daily for up to 14 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

57 mg or 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis; and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

Each chewable tablet contains 57 or 227 mg firocoxib.

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

9.0 mg/mL

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

0.045 mg/lb (0.1 mg/kg) of body weight once daily for up to 14 days

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

57 mg or 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

57 mg and 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

57 mg and 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

57 mg firocoxib per tablet

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

One 57 mg tablet administered orally to horses weighing 800 – 1300 lbs, once daily for up to 14 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Horse

Composition / specifications

Each milligram (mg) of paste contains 0.82 mg firocoxib.

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis.

Dosage

0.1 mg per kilogram (0.045 mg per pound) body weight daily for up to 14 days.

Limitations

Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

57 mg firocoxib

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

Administer one 57 mg tablet daily for horses weighing 800-1300 lbs for up to 14 days duration.

Limitations

For use in horses only. Do not use in horses intended for human consumption.

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

20 mg firocoxib per mL

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

Limitations

Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.

FDA page: Open in Animal Drugs @ FDA

Usage

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Vomiting (1) • Dog Loss of appetite (1) • Dog

Showing top 5 for Digestive.

Skin & allergy

Joint swelling (1) • Dog

Showing top 5 for Skin & allergy.

Neurologic

Unsteady walking (1) • Dog Tiredness (1) • Dog

Showing top 5 for Neurologic.

Effectiveness

Lack of efficacy - NOS (1) • Dog

Showing top 5 for Effectiveness.

Other

Limb non-weight bearing (1) • Cat Leucopenia NOS (1) • Dog Leucocytosis NOS (1) • Dog Hyperthermia (1) • Dog Haematuria (1) • Dog

Show more (21)

Gastric ulcer (1) • Dog Fluid in abdomen NOS (1) • Dog Faecal incontinence (1) • Dog Facial paralysis (1) • Dog Facial palsy (1) • Dog Elevated liver enzymes NOS (1) • Cat Elevated creatinine (1) • Dog Elevated blood urea nitrogen (1) • Dog Dry heaving (1) • Dog Distension of abdomen (1) • Dog Death by euthanasia (1) • Dog Death (1) • Dog Cold feeling of extremity (1) • Cat Bone and joint disorder NOS (1) • Dog Bloated (1) • Dog Agitation (1) • Dog Administration error NOS (1) • Cat Accidental exposure (1) • Cat Abnormal ultrasound finding (1) • Dog Abnormal radiograph finding (1) • Dog Abdominal pain (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Saint Bernard Dog, Male, 10 year, 58.06 kilogram • Drug: MSK, Tablet, chewable, Unknown, Dose: 1 tablet per animal, Frequency: 1 per day • Reactions: Elevated blood urea nitrogen, Elevated creatinine • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-075505
Serious AE: No
Treated For AE: No
Sex: Male
Age: 10.00 Year
Weight: 58.060 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Tablet, chewable
Dose: 1 tablet per animal
Frequency: 1 per day

Reactions Reported:

Elevated blood urea nitrogen Elevated creatinine

Outcomes: Outcome Unknown

Dog, ['Pit Bull', 'Dog (unknown)'], Female, 11.5 year, 37.376 kilogram • Drug: MSK, Tablet, chewable, Unknown • Reactions: Joint swelling, Bone and joint disorder NOS, Sarcoma NOS • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-074653
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 11.50 Year
Weight: 37.376 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Tablet, chewable

Reactions Reported:

Joint swelling Bone and joint disorder NOS Sarcoma NOS

Outcomes: Ongoing

Dog, Retriever - Labrador, Male, 13 year, 24.494 kilogram • Drug: MSK, Tablet, chewable, Oral • Reactions: Bloated, Staggering, Death, Dry heaving, Distension of abdomen • Outcome: Died

Report ID: USA-USFDACVM-2025-US-071673
Serious AE: Yes
Treated For AE: No
Sex: Male
Age: 13.00 Year
Weight: 24.494 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Tablet, chewable

Reactions Reported:

Bloated Staggering Death Dry heaving Distension of abdomen

Outcomes: Died

Dog, Retriever - Labrador, Female, 9 year, 44.452 kilogram • Drug: MSK, Tablet, chewable, Unknown • Reactions: Vomiting, Not eating, Low platelet count • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-074731
Serious AE: No
Treated For AE: Yes
Sex: Female
Age: 9.00 Year
Weight: 44.452 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Tablet, chewable

Reactions Reported:

Vomiting Not eating Low platelet count

Outcomes: Outcome Unknown

Dog, ['Boxer (German Boxer)', 'Dog (other)'], Male, 10 year, 21.047 kilogram • Drug: MSK, Tablet, chewable, Unknown • Reactions: Musculoskeletal disorder NOS, Unsteady walking (ataxia), Weakness, Agitation, Panting… • Outcome: Euthanized

Report ID: USA-USFDACVM-2025-US-073418
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 10.00 Year
Weight: 21.047 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Tablet, chewable

Reactions Reported:

Musculoskeletal disorder NOS Unsteady walking (ataxia) Weakness Agitation Panting Death by euthanasia

Outcomes: Euthanized

Dog, ['Boxer (German Boxer)', 'Retriever (unspecified)', 'Bulldog - English'], Male, 10 year, 21.047 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Musculoskeletal disorder NOS, Unsteady walking (ataxia), Weakness, Agitation, Panting… • Outcome: Euthanized

Report ID: USA-USFDACVM-2025-US-065912
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 10.00 Year
Weight: 21.047 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Musculoskeletal disorder NOS Unsteady walking (ataxia) Weakness Agitation Panting Death by euthanasia

Outcomes: Euthanized

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Firocoxib

Data freshness

Firocoxib

Medication Snapshot

Firocoxib

Indications / Uses

Warnings / Contraindications

Side Effects

FAQ

What species is this commonly shown for?

Does this usually require a prescription?

What dosage forms are listed?

Related Conditions

Source Transparency

Add to My Pet's Medications

Pet Owner Quick Guide

Next actions

Medication Research Insights

What to know

Evidence tension

Reaction signal map

Species and breed lens

What your vet may verify

What to watch next

Evidence

Vet Fast Scan

Quick Facts

Warnings / Contraindications

Adverse Reactions

Reported case explorer

USA-USFDACVM-2025-US-075505

USA-USFDACVM-2025-US-074653

USA-USFDACVM-2025-US-071673

USA-USFDACVM-2025-US-074731

USA-USFDACVM-2025-US-073418

USA-USFDACVM-2025-US-065912

Grouped by Body System

Most Reported Reactions

Source Documents

Owner handouts

Official label / PI

SPL

FOI

A-200755-G-0020-FL-AA_CIS.pdf

A-200755-G-0020-FL-AA_PI.pdf

N-141230-C-0093-NL-AA_CIS.pdf

N-141230-C-0093-NL-AA_PI.pdf

A-200766-C-0004-NL-AA_PI.pdf

A-200766-C-0002-CP-AA_CIS.pdf

A-200751-G-0002-FL-AA_PI.pdf

A-200722-G-0004-FL-AA_CIS.pdf

FIROX TABLETS 227mg 180x LBL.pdf

N-141253-C-0057-NL-AA_CIS.pdf

N-141253-C-0057-NL-AA_PI.pdf

N-141458-C-0015-NL-AA_CIS.pdf

N-141458-C-0015-NL-AA_PI.pdf

UCM422151.pdf

UCM422171.pdf

Firocoxib Tablets for Horses

Firocoxib Tablets for Horses

Horses

Firocoxib

Firocoxib

Dogs

Previcox®

Previcox®

Dogs

EquiCoxib™

EquiCoxib™

Horses

Firocoxib Chewable Tablets for Dogs

Firocoxib Chewable Tablets for Dogs

Dogs

Firodyl™

Firodyl™

Dogs

Firox™

Firox™

Dogs

Firocoxib Tablets for Horses